Lysosomal Storage Disorders and Malignancy

Lysosomal storage disorders (LSDs) are infrequent to rare conditions caused by mutations that lead to a disruption in the usual sequential degradation of macromolecules or their transit within the cell. Gaucher disease (GD), a lipidosis, is among the most common LSD, with an estimated incidence of 1...

Full description

Bibliographic Details
Main Authors: Gregory M. Pastores, Derralynn A. Hughes
Format: Article
Language:English
Published: MDPI AG 2017-02-01
Series:Diseases
Subjects:
Online Access:http://www.mdpi.com/2079-9721/5/1/8
id doaj-41a6578f7b55424abbfbb43e8be4e611
record_format Article
spelling doaj-41a6578f7b55424abbfbb43e8be4e6112020-11-25T01:36:43ZengMDPI AGDiseases2079-97212017-02-0151810.3390/diseases5010008diseases5010008Lysosomal Storage Disorders and MalignancyGregory M. Pastores0Derralynn A. Hughes1Department of Medicine (Genetics), University College Dublin, Mater Misericordiae University Hospital, Dublin, IrelandRoyal Free London NHS Foundation Trust, University College London, London NW3 2QG, UKLysosomal storage disorders (LSDs) are infrequent to rare conditions caused by mutations that lead to a disruption in the usual sequential degradation of macromolecules or their transit within the cell. Gaucher disease (GD), a lipidosis, is among the most common LSD, with an estimated incidence of 1 in 40,000 among the Caucasian, non-Jewish population. Studies have indicated an increased frequency of polyclonal and monoclonal gammopathy among patients with GD. It has been shown that two major sphingolipids that accumulate in GD, namely, β-glucosylceramide 22:0 (βGL1-22) and glucosylsphingosine (LGL1), can be recognized by a distinct subset of CD1d-restricted human and murine type II natural killer T (NKT) cells. Investigations undertaken in an affected mouse model revealed βGL1-22- and LGL1-specific NKT cells were present and constitutively promoted the expression of a T-follicular helper (TFH) phenotype; injection of these lipids led to downstream induction of germinal center B cells, hypergammaglobulinemia, and the production of antilipid antibodies. Subsequent studies have found clonal immunoglobulin in 33% of sporadic human monoclonal gammopathies is also specific for the lysolipids LGL1 and lysophosphatidylcholine (LPC). Furthermore, substrate reduction ameliorated GD-associated gammopathy in mice. It had been hypothesized that chronic antigenic stimulation by the abnormal lipid storage and associated immune dysregulation may be the underlying mechanism for the increased incidence of monoclonal and polyclonal gammopathies, as well as an increased incidence of multiple myeloma in patients with GD. Current observations support this proposition and illustrate the value of investigations into rare diseases, which as ‘experiments of nature’ may provide insights into conditions found in the general population that continue to remain incompletely understood.http://www.mdpi.com/2079-9721/5/1/8lysosomegammopathymultiple myeloma
collection DOAJ
language English
format Article
sources DOAJ
author Gregory M. Pastores
Derralynn A. Hughes
spellingShingle Gregory M. Pastores
Derralynn A. Hughes
Lysosomal Storage Disorders and Malignancy
Diseases
lysosome
gammopathy
multiple myeloma
author_facet Gregory M. Pastores
Derralynn A. Hughes
author_sort Gregory M. Pastores
title Lysosomal Storage Disorders and Malignancy
title_short Lysosomal Storage Disorders and Malignancy
title_full Lysosomal Storage Disorders and Malignancy
title_fullStr Lysosomal Storage Disorders and Malignancy
title_full_unstemmed Lysosomal Storage Disorders and Malignancy
title_sort lysosomal storage disorders and malignancy
publisher MDPI AG
series Diseases
issn 2079-9721
publishDate 2017-02-01
description Lysosomal storage disorders (LSDs) are infrequent to rare conditions caused by mutations that lead to a disruption in the usual sequential degradation of macromolecules or their transit within the cell. Gaucher disease (GD), a lipidosis, is among the most common LSD, with an estimated incidence of 1 in 40,000 among the Caucasian, non-Jewish population. Studies have indicated an increased frequency of polyclonal and monoclonal gammopathy among patients with GD. It has been shown that two major sphingolipids that accumulate in GD, namely, β-glucosylceramide 22:0 (βGL1-22) and glucosylsphingosine (LGL1), can be recognized by a distinct subset of CD1d-restricted human and murine type II natural killer T (NKT) cells. Investigations undertaken in an affected mouse model revealed βGL1-22- and LGL1-specific NKT cells were present and constitutively promoted the expression of a T-follicular helper (TFH) phenotype; injection of these lipids led to downstream induction of germinal center B cells, hypergammaglobulinemia, and the production of antilipid antibodies. Subsequent studies have found clonal immunoglobulin in 33% of sporadic human monoclonal gammopathies is also specific for the lysolipids LGL1 and lysophosphatidylcholine (LPC). Furthermore, substrate reduction ameliorated GD-associated gammopathy in mice. It had been hypothesized that chronic antigenic stimulation by the abnormal lipid storage and associated immune dysregulation may be the underlying mechanism for the increased incidence of monoclonal and polyclonal gammopathies, as well as an increased incidence of multiple myeloma in patients with GD. Current observations support this proposition and illustrate the value of investigations into rare diseases, which as ‘experiments of nature’ may provide insights into conditions found in the general population that continue to remain incompletely understood.
topic lysosome
gammopathy
multiple myeloma
url http://www.mdpi.com/2079-9721/5/1/8
work_keys_str_mv AT gregorympastores lysosomalstoragedisordersandmalignancy
AT derralynnahughes lysosomalstoragedisordersandmalignancy
_version_ 1725061359321743360